1. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
- Author
-
Daniel A R, Heisey, Timothy L, Lochmann, Konstantinos V, Floros, Colin M, Coon, Krista M, Powell, Sheeba, Jacob, Marissa L, Calbert, Maninderjit S, Ghotra, Giovanna T, Stein, Yuki Kato, Maves, Steven C, Smith, Cyril H, Benes, Joel D, Leverson, Andrew J, Souers, Sosipatros A, Boikos, and Anthony C, Faber
- Subjects
Cell Death ,bcl-X Protein ,Antineoplastic Agents ,Apoptosis ,Sarcoma, Ewing ,Poly(ADP-ribose) Polymerase Inhibitors ,Xenograft Model Antitumor Assays ,Piperazines ,Disease Models, Animal ,Mice ,Proto-Oncogene Proteins c-bcl-2 ,Drug Resistance, Neoplasm ,Cell Line, Tumor ,Animals ,Humans ,Phthalazines ,DNA Damage - Abstract
It was recently demonstrated that theWe employed a pair of cell lines derived from the same patient with Ewing sarcoma prior to and following chemotherapy, a panel of Ewing sarcoma cell lines, and several patient-derived xenograft (PDX) and cell line xenograft models.We found olaparib sensitivity was diminished following chemotherapy. The matched cell line pair revealed increased expression of the antiapoptotic protein BCL-2 in the chemotherapy-resistant cells, conferring apoptotic resistance to olaparib. Resistance to olaparib was maintained in this chemotherapy-resistant modelThese data reveal BCL-2 and BCL-X
- Published
- 2018